NRXP
NRX Pharmaceuticals, Inc.
$3.56
+1.42%
2026-08-21
About NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Key Fundamentals
Forward P/E
6.54
EPS (TTM)
$-1.04
Profit Margin
0.0%
Beta
2.18
Market Cap
$140.0M
Avg Volume (10D)
1.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$5.05
60D Low
$2.82
Avg Volume
1.2M
Latest Close
$3.56
Get breakout alerts for NRXP
Sign up for Breakout Scanner to receive daily notifications when NRXP triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
NRX Pharmaceuticals, Inc. (NRXP) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NRXP daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NRXP operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.